Pharmaphorum
Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare kidney disease FSGS.
Pharmaphorum
Shrugging off an earlier phase 3 disappointment, Travere's Filspari has become the first FDA-approved treatment for rare kidney disease FSGS.
Pharmaphorum
Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare kidney disease FSGS.